Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
4.830
-0.340 (-6.58%)
At close: Apr 3, 2025, 4:00 PM
4.910
+0.080 (1.66%)
After-hours: Apr 3, 2025, 8:00 PM EDT
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2024. The number of employees decreased by 700 or -43.75% compared to the previous year.
Employees
900
Change (1Y)
-700
Growth (1Y)
-43.75%
Revenue / Employee
$1,159,556
Profits / Employee
-$211,778
Market Cap
262.45M
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EBS News
- 3 days ago - Emergent BioSolutions Announces Stock Repurchase Program - GlobeNewsWire
- 14 days ago - Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - GlobeNewsWire
- 14 days ago - Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - GlobeNewsWire
- 15 days ago - Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - GlobeNewsWire
- 16 days ago - Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - GlobeNewsWire
- 21 days ago - Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - GlobeNewsWire
- 22 days ago - Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewsWire
- 24 days ago - Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International - GlobeNewsWire